Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Carson

Showing results (331-340 of 364) with videos related to

Pageof 37
Sort By:
Annals of Neurology|February 5, 1998
Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the ratK D Cliffer, J A Siuciak, S R Carson, et al.
Blood|September 23, 2011
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphomaTodd A Fehniger, Sarah Larson, Kathryn Trinkaus, et al.
The Oncologist|December 29, 2018
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory ApprovalSean Khozin, Kenneth R Carson, Jizu Zhi, et al.
Plos Genetics|May 8, 2007
Identification of the imprinted KLF14 transcription factor undergoing human-specific accelerated evolutionLayla Parker-Katiraee, Andrew R Carson, Takahiro Yamada, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 20, 2009
JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependenceEllen E Codd, John R Carson, Raymond W Colburn, et al.
Blood|January 9, 2017
Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphomaKilannin Krysiak, Felicia Gomez, Brian S White, et al.
Plos One|June 26, 2020
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemiaShamia Hoque, Brian J Chen, Martin W Schoen, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 13, 2006
The novel, orally active, delta opioid RWJ-394674 is biotransformed to the potent mu opioid RWJ-413216E E Codd, J R Carson, R W Colburn, et al.
British Journal of Haematology|December 3, 2015
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trialRanjana H Advani, Stephen M Ansell, Mary J Lechowicz, et al.
Clinical Pharmacology and Therapeutics|October 20, 2021
Real-World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in MenAlbert L Kraus, Michelle Yu-Kite, Jack Mardekian, et al.
Pageof 37

Showing results (331-340 of 364) with videos related to

Sort By:
Pageof 37
Annals of Neurology|February 5, 1998
Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the ratK D Cliffer, J A Siuciak, S R Carson, et al.
Blood|September 23, 2011
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphomaTodd A Fehniger, Sarah Larson, Kathryn Trinkaus, et al.
The Oncologist|December 29, 2018
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory ApprovalSean Khozin, Kenneth R Carson, Jizu Zhi, et al.
Plos Genetics|May 8, 2007
Identification of the imprinted KLF14 transcription factor undergoing human-specific accelerated evolutionLayla Parker-Katiraee, Andrew R Carson, Takahiro Yamada, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 20, 2009
JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependenceEllen E Codd, John R Carson, Raymond W Colburn, et al.
Blood|January 9, 2017
Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphomaKilannin Krysiak, Felicia Gomez, Brian S White, et al.
Plos One|June 26, 2020
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemiaShamia Hoque, Brian J Chen, Martin W Schoen, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 13, 2006
The novel, orally active, delta opioid RWJ-394674 is biotransformed to the potent mu opioid RWJ-413216E E Codd, J R Carson, R W Colburn, et al.
British Journal of Haematology|December 3, 2015
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trialRanjana H Advani, Stephen M Ansell, Mary J Lechowicz, et al.
Clinical Pharmacology and Therapeutics|October 20, 2021
Real-World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in MenAlbert L Kraus, Michelle Yu-Kite, Jack Mardekian, et al.
Pageof 37